Concepts (166)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Catheter Ablation | 26 | 2022 | 114 | 3.220 |
Why?
|
| Atrial Fibrillation | 25 | 2025 | 391 | 2.420 |
Why?
|
| Atrial Appendage | 6 | 2025 | 24 | 0.960 |
Why?
|
| Pulmonary Veins | 6 | 2021 | 19 | 0.630 |
Why?
|
| Anticoagulants | 5 | 2022 | 136 | 0.600 |
Why?
|
| Thrombosis | 2 | 2025 | 81 | 0.530 |
Why?
|
| Heart Atria | 5 | 2018 | 78 | 0.500 |
Why?
|
| Treatment Outcome | 24 | 2025 | 3438 | 0.490 |
Why?
|
| Death, Sudden, Cardiac | 4 | 2011 | 74 | 0.450 |
Why?
|
| Defibrillators, Implantable | 2 | 2011 | 36 | 0.430 |
Why?
|
| Arrhythmias, Cardiac | 2 | 2011 | 101 | 0.410 |
Why?
|
| Heart Diseases | 3 | 2025 | 116 | 0.350 |
Why?
|
| Preoperative Care | 3 | 2015 | 122 | 0.320 |
Why?
|
| Middle Aged | 25 | 2025 | 12125 | 0.310 |
Why?
|
| Kidney Diseases | 1 | 2011 | 250 | 0.290 |
Why?
|
| Humans | 37 | 2025 | 32798 | 0.280 |
Why?
|
| Postoperative Complications | 5 | 2016 | 828 | 0.280 |
Why?
|
| Aged | 19 | 2025 | 10538 | 0.270 |
Why?
|
| Thromboembolism | 2 | 2019 | 38 | 0.260 |
Why?
|
| Intraoperative Complications | 3 | 2018 | 59 | 0.260 |
Why?
|
| Female | 27 | 2025 | 20261 | 0.260 |
Why?
|
| Male | 27 | 2025 | 19641 | 0.260 |
Why?
|
| Device Removal | 3 | 2023 | 41 | 0.250 |
Why?
|
| Time Factors | 11 | 2019 | 2183 | 0.250 |
Why?
|
| Echocardiography, Transesophageal | 5 | 2022 | 58 | 0.240 |
Why?
|
| Esophageal Fistula | 2 | 2016 | 11 | 0.230 |
Why?
|
| Stroke Volume | 3 | 2015 | 370 | 0.230 |
Why?
|
| Patient Discharge | 2 | 2023 | 204 | 0.230 |
Why?
|
| Thrombectomy | 1 | 2025 | 75 | 0.220 |
Why?
|
| Stroke | 2 | 2019 | 609 | 0.200 |
Why?
|
| Prospective Studies | 9 | 2020 | 2327 | 0.200 |
Why?
|
| Tachycardia, Ventricular | 2 | 2016 | 27 | 0.200 |
Why?
|
| Risk Factors | 10 | 2019 | 3974 | 0.190 |
Why?
|
| Warfarin | 2 | 2015 | 34 | 0.190 |
Why?
|
| Adrenergic beta-Antagonists | 2 | 2015 | 63 | 0.190 |
Why?
|
| Follow-Up Studies | 7 | 2019 | 2284 | 0.190 |
Why?
|
| Esophagus | 2 | 2016 | 25 | 0.180 |
Why?
|
| Retrospective Studies | 7 | 2023 | 3701 | 0.180 |
Why?
|
| Hospitalization | 1 | 2023 | 488 | 0.170 |
Why?
|
| Body Surface Potential Mapping | 2 | 2018 | 14 | 0.160 |
Why?
|
| Heart Rate | 2 | 2018 | 343 | 0.150 |
Why?
|
| Vena Cava, Superior | 1 | 2018 | 5 | 0.150 |
Why?
|
| Cohort Studies | 4 | 2021 | 1844 | 0.140 |
Why?
|
| Patient Satisfaction | 2 | 2022 | 240 | 0.140 |
Why?
|
| Prevalence | 4 | 2017 | 1002 | 0.140 |
Why?
|
| Electrocardiography | 2 | 2014 | 636 | 0.130 |
Why?
|
| Heart Conduction System | 2 | 2015 | 78 | 0.130 |
Why?
|
| Thyroid Hormones | 1 | 2017 | 6 | 0.130 |
Why?
|
| Feasibility Studies | 3 | 2025 | 308 | 0.130 |
Why?
|
| Cardiomyopathy, Dilated | 1 | 2016 | 17 | 0.130 |
Why?
|
| Cicatrix | 1 | 2016 | 39 | 0.120 |
Why?
|
| Hot Temperature | 1 | 2016 | 78 | 0.120 |
Why?
|
| Pericardial Effusion | 1 | 2016 | 9 | 0.120 |
Why?
|
| Sinoatrial Node | 1 | 2015 | 4 | 0.120 |
Why?
|
| Tachycardia, Sinus | 1 | 2015 | 5 | 0.120 |
Why?
|
| Surgery, Computer-Assisted | 2 | 2015 | 57 | 0.120 |
Why?
|
| Recurrence | 4 | 2021 | 282 | 0.120 |
Why?
|
| Balloon Occlusion | 1 | 2016 | 37 | 0.120 |
Why?
|
| Survival Rate | 3 | 2015 | 894 | 0.110 |
Why?
|
| Atrial Flutter | 1 | 2015 | 19 | 0.110 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2015 | 134 | 0.110 |
Why?
|
| Predictive Value of Tests | 3 | 2015 | 887 | 0.110 |
Why?
|
| Amiodarone | 1 | 2014 | 5 | 0.110 |
Why?
|
| Anti-Arrhythmia Agents | 1 | 2014 | 16 | 0.110 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2015 | 81 | 0.110 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2015 | 136 | 0.110 |
Why?
|
| International Normalized Ratio | 2 | 2015 | 9 | 0.110 |
Why?
|
| Migraine Disorders | 1 | 2015 | 69 | 0.110 |
Why?
|
| Sleep Apnea, Obstructive | 1 | 2014 | 57 | 0.100 |
Why?
|
| Comorbidity | 2 | 2016 | 573 | 0.100 |
Why?
|
| Heart Failure | 2 | 2011 | 695 | 0.100 |
Why?
|
| Chronic Disease | 2 | 2014 | 410 | 0.100 |
Why?
|
| Ventricular Function, Left | 1 | 2015 | 252 | 0.100 |
Why?
|
| Exercise Test | 1 | 2014 | 223 | 0.100 |
Why?
|
| Incidence | 5 | 2015 | 1238 | 0.100 |
Why?
|
| Stents | 1 | 2014 | 174 | 0.100 |
Why?
|
| Heart Defects, Congenital | 1 | 2013 | 32 | 0.100 |
Why?
|
| Adult | 7 | 2015 | 9560 | 0.100 |
Why?
|
| Laser Therapy | 1 | 2013 | 56 | 0.090 |
Why?
|
| United States | 6 | 2019 | 4108 | 0.090 |
Why?
|
| Pacemaker, Artificial | 1 | 2013 | 35 | 0.090 |
Why?
|
| Severity of Illness Index | 2 | 2015 | 881 | 0.090 |
Why?
|
| Equipment Design | 3 | 2021 | 179 | 0.090 |
Why?
|
| Proportional Hazards Models | 2 | 2015 | 764 | 0.090 |
Why?
|
| Life Style | 1 | 2014 | 407 | 0.090 |
Why?
|
| Drug Administration Schedule | 3 | 2019 | 271 | 0.090 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2016 | 1066 | 0.090 |
Why?
|
| Quality of Life | 2 | 2015 | 961 | 0.090 |
Why?
|
| Sodium Channels | 1 | 2011 | 16 | 0.090 |
Why?
|
| Robotics | 1 | 2012 | 127 | 0.080 |
Why?
|
| Heart Ventricles | 1 | 2011 | 146 | 0.080 |
Why?
|
| Glomerular Filtration Rate | 1 | 2011 | 309 | 0.080 |
Why?
|
| Muscle, Smooth | 1 | 2010 | 69 | 0.080 |
Why?
|
| Prognosis | 4 | 2016 | 1544 | 0.080 |
Why?
|
| Enoxaparin | 1 | 2010 | 21 | 0.080 |
Why?
|
| Aged, 80 and over | 4 | 2025 | 4032 | 0.080 |
Why?
|
| Muscle Contraction | 1 | 2010 | 113 | 0.080 |
Why?
|
| Cardiac Pacing, Artificial | 1 | 2009 | 12 | 0.080 |
Why?
|
| Myocardial Infarction | 2 | 2016 | 483 | 0.080 |
Why?
|
| Chi-Square Distribution | 1 | 2010 | 292 | 0.080 |
Why?
|
| Disease-Free Survival | 3 | 2015 | 326 | 0.070 |
Why?
|
| Decision Support Systems, Clinical | 1 | 2009 | 64 | 0.070 |
Why?
|
| Ventricular Fibrillation | 1 | 2008 | 7 | 0.070 |
Why?
|
| Survival Analysis | 1 | 2009 | 486 | 0.070 |
Why?
|
| Drug Prescriptions | 1 | 2008 | 58 | 0.070 |
Why?
|
| Age Factors | 1 | 2011 | 1197 | 0.070 |
Why?
|
| Electrocardiography, Ambulatory | 2 | 2018 | 26 | 0.060 |
Why?
|
| Fluoroscopy | 2 | 2017 | 39 | 0.060 |
Why?
|
| Body Temperature | 1 | 2006 | 20 | 0.060 |
Why?
|
| Coronary Artery Disease | 1 | 2009 | 413 | 0.060 |
Why?
|
| Registries | 2 | 2022 | 315 | 0.060 |
Why?
|
| Risk Assessment | 4 | 2016 | 1460 | 0.060 |
Why?
|
| North Carolina | 1 | 2010 | 1546 | 0.060 |
Why?
|
| Monitoring, Physiologic | 1 | 2006 | 77 | 0.060 |
Why?
|
| Texas | 2 | 2016 | 40 | 0.060 |
Why?
|
| Evidence-Based Medicine | 2 | 2016 | 215 | 0.050 |
Why?
|
| Ultrasonography, Interventional | 1 | 2021 | 52 | 0.040 |
Why?
|
| Cross-Over Studies | 1 | 2020 | 98 | 0.040 |
Why?
|
| Dobutamine | 1 | 2020 | 55 | 0.040 |
Why?
|
| Echocardiography, Doppler, Color | 1 | 2019 | 5 | 0.040 |
Why?
|
| Phrenic Nerve | 1 | 2018 | 5 | 0.040 |
Why?
|
| Young Adult | 2 | 2015 | 2730 | 0.030 |
Why?
|
| Propensity Score | 1 | 2017 | 48 | 0.030 |
Why?
|
| Electrophysiologic Techniques, Cardiac | 1 | 2016 | 3 | 0.030 |
Why?
|
| Stethoscopes | 1 | 2016 | 1 | 0.030 |
Why?
|
| Thermodynamics | 1 | 2016 | 48 | 0.030 |
Why?
|
| Hormone Replacement Therapy | 1 | 2017 | 89 | 0.030 |
Why?
|
| Monitoring, Intraoperative | 1 | 2016 | 44 | 0.030 |
Why?
|
| Premedication | 1 | 2016 | 16 | 0.030 |
Why?
|
| Echocardiography | 1 | 2017 | 182 | 0.030 |
Why?
|
| Adolescent | 2 | 2015 | 3638 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2018 | 532 | 0.030 |
Why?
|
| Europe | 1 | 2015 | 83 | 0.030 |
Why?
|
| Genetic Markers | 1 | 2016 | 125 | 0.030 |
Why?
|
| Genetic Association Studies | 1 | 2016 | 148 | 0.030 |
Why?
|
| Italy | 1 | 2015 | 15 | 0.030 |
Why?
|
| Telemetry | 1 | 2015 | 29 | 0.030 |
Why?
|
| Isoproterenol | 1 | 2014 | 17 | 0.030 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 1 | 2015 | 54 | 0.030 |
Why?
|
| Adrenergic beta-Agonists | 1 | 2014 | 30 | 0.030 |
Why?
|
| Action Potentials | 1 | 2015 | 186 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2016 | 622 | 0.030 |
Why?
|
| Research Design | 1 | 2016 | 331 | 0.030 |
Why?
|
| Patient Selection | 1 | 2015 | 281 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2015 | 565 | 0.030 |
Why?
|
| Reoperation | 1 | 2014 | 260 | 0.020 |
Why?
|
| Attitude to Health | 1 | 2014 | 163 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2016 | 835 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2016 | 1572 | 0.020 |
Why?
|
| Health Care Surveys | 1 | 2012 | 186 | 0.020 |
Why?
|
| Amino Acid Substitution | 1 | 2011 | 40 | 0.020 |
Why?
|
| Heterozygote | 1 | 2011 | 61 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2013 | 876 | 0.020 |
Why?
|
| Alleles | 1 | 2011 | 253 | 0.020 |
Why?
|
| Vasoconstriction | 1 | 2010 | 43 | 0.020 |
Why?
|
| Clinical Competence | 1 | 2012 | 338 | 0.020 |
Why?
|
| Coronary Angiography | 1 | 2009 | 162 | 0.020 |
Why?
|
| Cardiovascular Diseases | 1 | 2016 | 1140 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2009 | 576 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2009 | 767 | 0.020 |
Why?
|
| Hospital Mortality | 1 | 2008 | 205 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2008 | 682 | 0.020 |
Why?
|
| Clinical Trials as Topic | 1 | 2008 | 307 | 0.020 |
Why?
|
| Child | 1 | 2013 | 2478 | 0.020 |
Why?
|
| Logistic Models | 1 | 2008 | 783 | 0.020 |
Why?
|
| Cryosurgery | 1 | 2006 | 23 | 0.020 |
Why?
|